drugset / Trial / NCT03842904

A Study Comparing the Effects of Trimbow to Fostair in COPD

NCT03842904

Phase 4 Completed 23 enrolled Medicines Evaluation Unit Ltd Chiesi UK · collab
RandomizedCrossoverOpen-labelTreatment

Summary

A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation in moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2018-12-13
Primary completion
2019-07-30
Completion
2019-08-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 5 ug
Comparator Formoterol Other / unclassified 6 ug
Subject Glycopyrronium Unknown 9 ug
Comparator beclomethasone dipropionate Other / unclassified 87 ug Inhaled
Comparator beclomethasone dipropionate Other / unclassified 100 ug Inhaled